The U.S. Food and Drug Administration on Nov. 17 announced the Global Reliance Disclosure Program, an initiative the agency said will transform how its regulatory drug and biologic approval decisions are leveraged by health authorities around the world and may accelerate patient access to innovative therapies.
The program enables the FDA to more efficiently share minimally redacted approval packages, including the agency's detailed scientific and regulatory assessments, directly with companies who can then share them with regulatory authorities outside the United States, "empowering those authorities to rely on the FDA's rigorous, science-based review decisions rather than conducting duplicative and time-consuming product evaluations of their own, while maintaining sovereignty over their regulatory decision," the FDA said. "The GRDP is a prime example of America First policies improving public health worldwide," said Grace Graham, FDA deputy commissioner for policy, legislation, and international affairs. "The FDA is the global gold standard and making it easier for applicants to leverage our detailed scientific assessments to facilitate faster access for patients everywhere is an example of America's continued interest in advancing global health under the Trump Administration."
The program launched on Oct. 30, with a President's Emergency Plan for AIDS Relief tentative approval for lenacapavir, a drug indicated for both HIV prevention and treatment. The FDA called that "an especially meaningful starting point given PEPFAR's life-saving mission to combat HIV/AIDS in some of the world's most vulnerable populations." The GRDP is currently available to PEPFAR tentative approvals, excluding tentatively approved abbreviated new drug application products. The agency intends to expand the program in January 2027 to all novel drugs and biologics, specifically New Molecular Entity New Drug Applications and 351(a) Biologics License Applications. The FDA also intends to launch a pathway in early 2027 to expedite an applicant's ability to request their minimally redacted action packages for approved and licensed drugs and biologics already on the U.S. market.
To receive a minimally redacted application approval package under the program, applicants must request to participate within 10 calendar days of approval and confirm the application package is being submitted to a foreign regulatory authority in support of a marketing application. Applicants with eligible applications will receive detailed information in FDA approval letters, and the agency intends to provide the package on an expedited basis. Requests for minimally redacted approval packages for other purposes will not be processed under the GRDP and should be submitted as a Freedom of Information Act request, the FDA said. "In an era of increasing global interdependence in pharmaceutical development and supply chains, the FDA's leadership is most effective when it is collaborative," said Mark Abdoo, associate commissioner for global policy and strategy. The agency said the program addresses the gap between regulatory approval in high-capacity countries and patient access in lower-resource settings, where patients may wait months or years longer for an independent national review, and that harmonized regulatory decisions reduce the risk of fragmented or inconsistent product standards across markets. This is a disclosure-and-sharing program, not a change to U.S. approval standards, and not a new approval of lenacapavir in the United States beyond the PEPFAR tentative approval the FDA cited as the launch case.
